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Abstract Dasatinib is an orally active small molecule
kinase inhibitor of both the src and abl proteins. To
evaluate the potential role of dasatinib in breast cancer
we used 39 human breast cancer cell lines that have
been molecular profiled using Agilent Microarrays.
They represent both luminal and basal breast cancer
subtypes based on the relative gene expression of cy-
tokeratin (CK) 8/CK18 and CK5/CK17, respectively,
and those that have undergone an epithelial-to-
mesenchymal transition (post-EMT) based on their
expression of vimentin and the loss of CKs. When
treated with 1 lM dasatinib in vitro 8 of them were
highly sensitive (>60% growth inhibition), 10 of them
were moderately sensitive (40–59% growth inhibition),
and 21 were resistant to dasatinib. A highly significant
relationship between breast cancer subtype and sensi-
tivity to dasatinib was observed (v2 = 9.66 and
P = 0.008). Specifically, basal-type and post-EMT
breast cancer cell lines were most sensitive to growth
inhibition by dasatinib. In an attempt to identify po-
tential predictive markers of dasatinib response other
than breast cancer subtype we analyzed the baseline
gene expression profiles for differentially expressed
genes. We identified a set of three biologically relevant
genes whose elevated expression is associated with
dasatinib inhibition including moesin, caveolin-1, and
yes-associated protein-1 with a sensitivity and specific-
ity of 88 and 86%, respectively. Importantly, these data
provide scientific rationale for the clinical development
of dasatinib in the treatment of women with ‘‘triple-
negative’’ breast cancer, a subtype that is categorized as
being aggressive and lacking effective treatments (i.e.
hormonal manipulation or trastuzumab).
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Introduction
Breast cancer affects over one million women world-
wide every year [1–3]. Advances in our understanding
of the biology of this disease have lead to improved
patient survival with incorporation of new anti-hor-
monal agents in the treatment of hormone receptor
positive disease and the addition of HER-2 directed
therapies for the 25% of women with HER-2 amplifi-
cation [4–5]. There remains however, a subset of
women for whom these approaches are not an effective
option and chemotherapy offers only limited benefits.
This group has been described as ‘‘triple-negative’’ (i.e.
estrogen receptor negative, progesterone receptor
negative, and HER-2 negative) and represents a dis-
tinct clinical and molecular subgroup of the disease.
Recent studies using gene expression profiling have
identified this group as expressing unique cytokeratins
that differentiate it from other types of breast cancer
and as having a similar poor prognosis to the HER-2
positive group prior to the introduction of trastuzumab
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[6–8]. Profiling data have subgrouped the disease into
‘‘luminal’’, expressing specific cytokeratins (CK8,
CK18) associated with the luminal layer in the normal
breast epithelium, or the ‘‘basal’’ group based on the
expression of cytokeratins (CK5, CK17) found in the
basal layer of the breast epithelium. ER+ and HER-2
amplified disease may occur in both subtypes, whereas
the ‘‘triple-negative’’ breast cancers are generally of
the basal subtype [6–9]. In addition, there exists a
subset of ‘‘triple-negative’’ breast cancers that also
express vimentin. This group is felt to represent breast
cancers that have undergone an epithelial-to-
mesenchymal transition (EMT) and has been associ-
ated with clinical disease that is more invasive, has a
higher mitotic index, and also has a worse clinical
outcome [10, 11]. Taken together, these data demon-
strate that the identification of new therapies with
activity in the basal subtype of breast cancer is a clin-
ical priority.
c-src is the cellular homolog of the viral oncogene
v-src and is the prototypic member of a family of non-
receptor tyrosine kinases that play a key role in many
cellular signaling pathways that involve proliferation,
differentiation, survival, motility, and angiogenesis.
Aberrant expression and activation of src-family kin-
ases have been implicated in a number of human
malignancies but thus far they have not proven to be
effective clinical targets [12–13]. Despite this, molecu-
lar studies continue to show src to play a potential role
in clinically important pathways in breast cancer
including the steroid and peptide hormone signaling
pathways [14–15].
Dasatinib is an orally active small molecule inhibitor
of both the src and abl proteins with IC50s for the
isolated kinases of 0.55 and 3.0 nM, respectively [16].
Recently, dasatinib was approved for the treatment of
imatinib refractory chronic myelogenous leukemia
(CML) and bcr–abl positive acute lymphoblastic leu-
kemia (ALL) [17–18]. To determine the potential
clinical role of a src-inhibitor in breast cancer, we
examined the in vitro effects of dasatinib in an unbi-
ased fashion using a panel of 39 human breast cancer
cell lines that have been characterized using tran-
scriptional profiling with the Agilent platform [19].
These studies demonstrated that dasatinib significantly
inhibited proliferation of those cells lines that repre-
sent the basal subtype of human breast cancer. In
addition, there was a minority of luminal-type cell lines
that also demonstrated some sensitivity to dasatinib.
Using the baseline gene expression profiles for this
panel of cell lines, we generated a three-gene ‘‘pre-
dictive’’ set with a high sensitivity and specificity (88%
and 85%, respectively) that identifies those breast
cancer cells most likely to respond to dasatinib.
Caveolin-1 (CAV1), moesin (MSN), and yes-associated
protein (YAP1) were not only found to be differen-
tially expressed in the most sensitive cell lines, but their
association with src signaling pathways lends credence
to their relevance as potential biomarkers. The obser-
vation that dasatinib preferentially inhibited the
growth of basal-type breast cancer cell lines has also
been made independently and simultaneously by Clark
et al. [20] using a different array platform (Affymetrix),
different cell lines, and different assays for prolifera-
tion. Together, these data support the clinical testing of
dasatinib in breast cancer, and specifically the ‘‘triple-
negative’’ population, which at this time represents an
unmet medical need.
Materials and methods
Cell lines, cell culture, and reagents
The effects of dasatinib on cell growth were studied
in human breast cancer cell lines growing in vitro.
The cell lines MDA-MB-415, MDA-MB-134, HCC-
1500, ZR-75-30, HCC-202, HCC-1419, HCC-38,
HCC-70, HCC-1187, HCC-1806, HCC-1937, HCC-
1954, MDA-MB-436, HCC-1569, Hs578t, HCC-1143,
MDA-MB-175, BT-474, SK-BR-3, MDA-MB-361,
UAC-893, UACC-812, UACC-732, T-47D, MDA-
MB-453, MDA-MB-468, CAMA-1, MDA-MB-157,
MCF-7, MDA-MB-435, ZR-75-1, BT-20, and MDA-
MB-231 were obtained from American Type Culture
Collection (Rockville, MD). The cell lines EFM-
192A, KPL-1, EFM-19 and CAL-51 were obtained
from the German Tissue Repository DSMZ (Braun-
schweig Germany), and the cell lines SUM-190 and
SUM-225 were obtained from the University of
Michigan (Ann Arbor, MI). MDA-MB-134, MDA-
MB415, MDA-MB-436, MDA-MB-175, UACC-893,
UACC-812, and MDA-MB-157 cells were cultured in
L15 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2 mmol/L glutamine and
1% peniclin G-streptomycin-fungizone solution (PSF,
Irvine Scientific, Santa Ana, CA). CAL-51, KPL-1,
Hs578t cells were grown in DMEM supplemented
with 10% heat-inactivated FBS and PSF, as above.
SUM-190 and SUM-225 cells were cultured in
HAM’s F12 supplemented with 5% heat-inactivated
FBS, PSF, 5 mg/ml insulin and 1 mg/ml hydrocorti-
sone. The remaining cell lines were cultured in RPMI
1640 supplemented with 10% heat-inactivated FBS,
2 mmol/L glutamine, and PSF.
320 Breast Cancer Res Treat (2007) 105:319–326
123
Microarray analysis of cell lines
Agilent microarray analyses were developed for each
cell line [19]. Briefly, cells were grown to log phase and
then RNA was extracted using the RNeasy Kit (Qia-
gen). The purified RNA was eluted in 30–60 ll DEPC
water and the quantity of RNA measured by spectral
analysis using the Nanodrop Spectrophotometer. RNA
quality was determined by separation of the RNA via
capillary electrophoresis using the Agilent 2000 Bio-
analyzer. Microarrays of breast cancer cell lines were
then performed on the Agilent Human 1A V1 chip.
Characterization of individual breast cancer cell lines
by comparison to a breast cell line mixed reference
pool was conducted on a single slide in which the
mixed pool RNA was labeled with cyanine-3 and the
individual cell lines with cyanine-5. The mixed refer-
ence pool consisted of equal amounts of cRNA from
ten breast cancer cell lines that were selected to be
representative of a range of the various known breast
cancer subtypes based on their expression of specific
molecular markers, e.g. ESR1, HER-2, EGFR, as well
as growth characteristics. The reference includes the
following cell lines: 184B5, MDA-MB-468, MDA-MB-
157, MDA-MB-231, MDA-MB-175, CAMA-1, MCF-
7, MDA-MB-361, SK-BR-3, and DU4475. Microarray
slides were read using an Agilent Scanner and the
Agilent Feature Extraction software version 7.5 was
used to calculate gene expression values. Extracted
data was imported into Rosetta Resolver 5.1 to create
expression profiles for each individual breast cell line
experiment. Cluster analysis was performed in Re-
solver and cell line profiles were exported to Excel
(Microsoft) for additional analysis of the distribution
of gene expression changes across the various subtypes
and the individual cell line response data.
Proliferation assays
Cells were seeded in duplicate at 5,000 to 10,000 cells
per well in 24-well plates. The day after plating,
dasatinib was added at a final concentration of 1 lM.
Control wells without drug were seeded as well. Both
the adherent and floating fractions of cells were
counted on days 2, 5 and 7 for both treatment and
control wells. After trypsinization cells were placed in
Isotone solution and counted immediately using a
Coulter Z2 particle counter (Beckman Coulter Inc,
Fullerton, CA).
Growth inhibition was calculated [(1-experimental
value/control value) · 100] for each day adding both
the values obtained for the floating cells and the
adherent cells. Pearson Chi-squares analysis was per-
formed to identify a correlation between subtype and
sensitivity to dasatinib. Dasatinib was provided by
Frank Lee at Bristol-Meyers-Squibb.
Statistical methods
Pearson Chi-squared tests were performed using Stat-
istica 7.1 (Statsoft Inc) to determine the relationship (if
any) between subtype and dasatinib response. Genes
potentially related to response were determined by
analyzing the distribution of samples with significant
expression changes across cell line groups defined by
subtype and response for each gene. The threshold
for up-regulation was set to log (ratio) >0.13 with a
P-value < 0.01 and down-regulation was defined as log
(ratio) <–0.13 with a P-value < 0.01. The P-values were
determined according to the Agilent error model when
the feature-extracted data was imported into Resolver.
Gene ontology and pathway information was used to
further constrain the set of candidate markers. Clus-
tering was then used to visualize expression of candi-
date markers across all the cell lines tested for
dasatinib response to develop a potentially sensitive
and specific ‘‘response predictor marker set’’ of genes.
Results
Dasatinib inhibits growth of ‘‘basal-type’’ breast
cancer
A total of 39 breast cancer cell lines were categorized
as representing luminal or basal breast cancer subtypes
based on the relative gene expression of cytokeratins
(CK) 8/CK18 and CK5/CK17, respectively. In addition,
several cell lines were classified as representing breast
cancers that had undergone an epithelial-to-mesen-
chymal transition (post-EMT) based on their expres-
sion of vimentin and the loss of cytokeratin expression.
A cluster diagram of the 39 breast cancer cell lines
versus 5 subtype markers was developed (Fig. 1). The
cell lines that show mixed cytokeratin expression were
classified as primarily basal based on the lack of
expression of several additional well-characterized
luminal markers: e.g. estrogen receptor, E-cadherin
(CDH1), and GATA3 (Data not shown.) The relative
expression of the above markers as well as estrogen
receptor and HER-2 expression levels were used to
assign the various cell lines into previously clinically
defined subtypes [6–8]. Response to dasatinib was then
assigned to each cell line along with the subtype of
breast cancer it represents (Table 1). Proliferation
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responses were based on the level of inhibition at 1 lM
of dasatinib with those cell lines having greater than
60% inhibition being assigned to the highly sensitive
group, those with 40–59% inhibition being assigned to
the moderately sensitive group, and those with <40%
inhibition at 1 lM assigned to the resistant group. This
separation was based on the fact that serum concen-
trations greater than 1 lM are unlikely to be achieved
in patients with solid tumors (BMS personal commu-
nication). The moderately sensitive and highly sensi-
tive cell lines were grouped as ‘‘Sensitive’’ in the
Chi-square test and demonstrate a highly significant
relationship between sensitivity to dasatinib and the
basal subtype of breast cancer cell lines with v2 = 9.66
and P = 0.008 (Table 2).
Expression of a three gene subset predicts response
to dasatinib with a specificity and sensitivity of 88%
and 86% respectively across subtypes
In addition, there were some luminal cell lines that
demonstrated moderate sensitivity to dasatinib
(Table 1). We therefore sought to identify a specific
gene subset that might allow us to identify all cell lines
that are responsive to dasatinib with a high sensitivity
and specificity. Using the baseline gene expression
profiles, we developed data matrices of differentially
expressed genes in an attempt to identify potential
predictive markers of dasatinib response. Initially
genes were sought that differentiated the sensitive
basal cell lines from resistant basal and luminal cell
lines. This analysis yielded both moesin and caveolin-1
as potential discriminators. Next, using a similar tech-
nique we sought to identify genes that discriminated
between the luminal cell lines that were sensitive and
resistant. yes-associated protein-1 (YAP-1) was iden-
tified based on its differential expression between the
two groups and potential biologic significance since
YAP-1 is a protein with relevance to src signaling. It is
a 65 kD protein that binds to the gene product of the
src-family kinase yes [21]. The relative expression lev-
els of these three genes in the cell line panel and their
associated response to dasatinib in vitro was evident
(Fig. 2). Detection of any one of these three markers
above the reference level is predictive of an in vitro
response to dasatinib with a sensitivity and specificity
of 88% and 86%, respectively (Table 3).
Discussion
The successful development of targeted therapeutics in
oncology has been hindered by the lack of reliable
predictive markers for response for any given agent.
Notable exceptions thus far have been the use of hor-
mone receptor measures [22] and tests for the presence
of the HER-2 alteration [23–26]. Unlike these two
examples, it has now become clear that for a number of
potential targets, simple measurement of gene
expression in clinical material may not necessarily
translate into clinical response or benefit for patients
[27, 28]. Ideally, as a novel agent enters the clinic, a
Fig. 1 Cluster diagram of relative gene expression of luminal
and basal markers including cytokeratins (KRT) 5,17 and 8, 18,
respectively as well as vimentin (VIM)
322 Breast Cancer Res Treat (2007) 105:319–326
123
target population of patients can be prospectively
identified that will likely benefit from that agent and
this information can then be used to guide clinical trial
design. In the current study, a large panel of human
breast cancer cell lines was molecularly characterized
using gene expression profiles in an unbiased fashion in
order to identify any subtype of breast cancers that
may be more likely to respond to dasatinib treatment.
Using a large panel better encompasses the molecular
heterogeneity of clinical breast cancers, including hor-
monally driven disease, HER-2 amplified disease, and
‘‘triple-negative’’ breast cancers. This panel was then
used to test the biologic effects of the multi-targeted
kinase inhibitor dasatinib. The effects of dasatinib on
proliferation were determined in an unbiased fashion
by testing the entire panel at 1 lM dasatinib. Recent
reports describe an additional approach to identify
signatures of oncogenic pathways by using DNA
microarrays of mammary epithelial cultures transfect-
ed with genes of interest, including src [29].
While aberrant activation and expression of src has
been implicated in breast cancer, its critical role has
not been associated with any distinct molecular phe-
notype. In this study we found a strong association
Table 1 Breast cancer
subtype classification based
on cytokeratin expression and
vimentin and response to
dasatinib
There is a significant
relationship between
response to dasatinib and
non-luminal subtype (Pearson
Chi-Squared P \ 0.0079)
Cell line Breast cancer subtype ER status HER-2 status Response to
dasatinib in vitro
MDA-MB-453 Luminal Neg Amplified Resistant
SK-BR-3 Luminal Neg Amplified Resistant
SUM-190 Luminal Neg Amplified Resistant
SUM-225 Luminal Neg Amplified Resistant
UACC-893 Luminal Neg Amplified Resistant
EFM-192A Luminal Pos Amplified Resistant
HCC-202 Luminal Pos Amplified Resistant
UACC-732 Luminal Pos Amplified Resistant
UACC-812 Luminal Pos Amplified Resistant
ZR-75-30 Luminal Pos Amplified Resistant
HCC-1500 Luminal Pos Normal Resistant
KPL-1 Luminal Pos Normal Resistant
MDA-MB-134 Luminal Pos Normal Resistant
MDA-MB-175 Luminal Pos Normal Resistant
MDA-MB-415 Luminal Pos Normal Resistant
ZR-75-1 Luminal Pos Normal Resistant
CAMA-1 Luminal Pos Normal Resistant
BT-474 Luminal Pos Amplified Moderately sensitive
HCC-1419 Luminal Pos Amplified Moderately sensitive
MDA-MB-361 Luminal Pos Amplified Moderately sensitive
EFM-19 Luminal Pos Normal Moderately sensitive
MCF-7 Luminal Pos Normal Moderately sensitive
T-47D Luminal Pos Normal Moderately sensitive
BT-20 Basal Neg Normal Resistant
HCC 38 Basal Neg Normal Resistant
MDA-MB-468 Basal Neg Normal Resistant
HCC-1954 Basal Neg Amplified Moderately sensitive
HCC-1143 Basal Neg Normal Moderately sensitive
HCC-1187 Basal Neg Normal Moderately sensitive
HCC-1937 Basal Neg Normal Moderately sensitive
HCC-1806 Basal Neg Normal Highly sensitive
HCC-70 Basal Neg Normal Highly sensitive
CAL-51 Post-EMT Neg Normal Highly sensitive
Hs578t Post-EMT Neg Normal Highly sensitive
MDA-MB-157 Post-EMT Neg Normal Highly sensitive
MDA-MB-231 Post-EMT Neg Normal Highly sensitive
MDA-MB-435 Post-EMT Neg Normal Highly sensitive
MDA-MB-436 Post-EMT Neg Normal Highly sensitive
HCC-1569 Post-EMT Neg Amplified Resistant
Table 2 Frequency table of observed response to dasatinib in
39 breast cancer cell lines classified into 3 subtypes
Breast cell line subtype
Luminal Basal Post-EMT Total
Dasatinib
response
Resistant 17 3 1 21
Sensitive 6 6 6 18
Total 23 9 7 39
v2 = 9.658 and P = 0.008
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between in vitro sensitivity to dasatinib and the basal
(‘‘triple-negative’’) subtype of human breast cancer.
Given the large amount of data surrounding the role of
src in HER-2 signaling, our hypothesis would be that
dasatinib might be active in cell lines with HER-2
amplification, however, most of these cell lines were
relatively resistant to monotherapy with dasatinib (11
of 15). In addition, the majority of sensitive cell lines
are steroid receptor low or negative. Together, these
characteristics alone define, in part, the ‘‘triple-
negative’’ group of breast cancer.
Using the baseline expression arrays we were able to
further discriminate ‘‘responsive’’ cell lines using the
differential expression of three genes: moesin, caveo-
lin, and yes-associated protein-1 with a high sensitivity
and specificity (88% and 86%, respectively). While
other genes may be derived from the analysis of large
microarray datasets, the biologic relevance of these
genes makes them plausible predictive markers for
defining a population of breast cancers that may re-
spond to a src-targeted therapeutic like dasatinib. In
addition, both moesin and caveolin-1 have been iden-
tified as markers for basal breast cancers [30, 31].
Caveolin-1 interacts closely with the src family kinase
(SFK), fyn, in linking integrins with ras-ERK signaling
in the focal adhesion pathway as well as other SFKs
[32, 33]. Moesin is a member of the ERM (Ezrin/
Radixin/Moesin) family of proteins which have been
shown to interact with src in adhesion-mediated
signaling [34, 35]. As stated above YAP-1 directly
interacts with src and another SFK proto-oncogene yes,
possibly in the tight junction and adherens pathways
[21, 36].
The src oncogene was the first transforming gene
described, however until recently it was not pursued
aggressively as a target in oncology. Unlike v-src, the
human cellular homologue c-src was found to be only
tumorigenic and felt by some not to play a large role in
the pathogenesis of human malignancies [13]. Re-
cently, however, aberrant activation and expression of
c-src has been associated with human disease, including
malignancies of the lung, skin, colon, ovary, endome-
trium, head and neck area and breast [12]. This has
lead to the current hypothesis that c-src may facilitate
the action of other signaling proteins, rather than being
a dominant transforming agent. On its own, c-src
interacts with a number of cellular factors including the
cell surface receptors of the EGFR family, CSFR-1,
PDGFR, and FGFR as well as integrins, cell-cell
adhesion molecules, steroid hormone receptors, com-
ponents of pathways regulated by G-protein coupled
receptors, and focal adhesion kinases (fak), as well as
adapter proteins such as shc and many others [12]. As a
result of its role in these critical pathways c-src is likely
to play a key role in the regulation of proliferation,
differentiation, survival, motility, angiogenesis, and
functions of differentiated cells [12]. It is known that
alterations in several of these processes are character-
istic of the malignant phenotype [37]. The current data
from our group as well as data independently gener-
ated by Clark et al. [20] indicate some dependence on
src signaling pathways in the basal subgroup of breast
Fig. 2 39 breast cancer cell
lines with relative expression
of moesin (MSN), caveolin-1
(CAV1), and yes-associated
protein-1 (YAP1) based on
baseline Agilent expression
profiles. Each cell line is
assigned a response based on
Table 1 (R = resistant,
M = moderately sensitive,
S = highly sensitive)
Table 3 Significant expression of one of the three genes moesin
(MSN), caveolin-1 (CAV1), and yes-associated protein-1
(YAP1) above the reference is associated with response to





Sensitive + Moderate Resistant
MSN, CAV1 or YAP1 > 0
P < 0.001
(TP) 15 (FP) 3
MSN, CAV1 or YAP1 < 0
P < 0.001
(FN) 2 (TN) 19
17 22
TP-true positive, FP-false positive, FN-false negative, TN-true
negative
Sensitivity = 15/17 = 88%
Sensificity = 19/22 = 86%
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cancers in vitro. Other recent research has supported
the role of src inhibition with dasatinib in head and neck,
pancreatic and lung cancer models as well [38–40].
Finally, mutations in the abl kinase are the defining
alteration in chronic myelogenous leukemia and have
been the basis for molecular targeting of that disease
initially with imatinib and now dasatinib. An alterna-
tive explanation for the current results could be based
on new data implicating abl in breast cancer. Evalua-
tion of abl activation in a panel of 8 breast cancer cell
lines has shown constitutive activation of abl in
‘‘aggressive breast cancer cells’’ without increases in
abl gene expression [41]. These cell lines included
many that were evaluated in our panel, including
MDA-MB-468, MCF-7, BT-474, SK-BR-3, MDA-MB-
231, MDA-MB-453, and UACC-893. Interestingly,
these authors described significantly increased abl
activity in the MDA-MB-231 and MDA-MB-435 cells.
In the current study, these cell lines are among those
highly sensitive to dasatinib and are classified as post-
EMT due to their expression of high levels of vimentin.
Also of interest is the observation that the basal cell
line MDA-MB-468 was one of only 3 basal cell lines
that we found to be resistant to dasatinib and in the
study implicating abl this cell line had a low level of abl
activation [41]. These data raise the possibility that abl
inhibition is another potential mechanism of dasatinib
activity in basal breast cancer cell lines. The final
determination of which of these two signaling path-
ways, i.e. src or abl, may be critical in basal breast
cancer will clearly require further study.
The pre-clinical in vitro activity of dasatinib in basal
breast cancer cell lines and the associated gene profile
will require validation in a clinical setting. In the cur-
rent study we concentrated on gene expression profiles.
mRNA studies may miss other important regulators of
protein levels or activation such as post-translational
modifications. However, two independent groups using
different array platforms and proliferation assays have
now made the observation that dasatinib is consider-
ably more active in basal-type breast cancer pre-
clinically. Currently, there are clinical studies planned
to evaluate dasatinib in solid tumors including breast
cancer, enriching for patients with ‘‘triple-negative’’ or
basal disease. Dasatinib may represent a new thera-
peutic option for women with this breast cancer sub-
type that has traditionally been associated with a poor
prognosis. Of note, recently this subtype has also been
shown to be increased in young African-American
women with breast cancer [42]. The pre-clinical plat-
form we applied to the study of dasatinib has provided
a hypothesis that is now ready for testing in the clinical
setting.
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